Revolutionary diagnostics with detection of molecular targets directly from whole blood
T2MR® technology powers all of the diagnostic innovations at T2 Biosystems. T2MR is a diagnostic detection method utilizing miniaturized magnetic resonance technology which measures how water molecules react in the presence of magnetic fields. Over 200 studies published in peer-reviewed journals have featured T2MR in a breadth of applications, including direct detection and measurement in targets such as whole blood, plasma, serum, saliva, sputum, and urine.
Time and labor savings in the lab
T2MR is the first and only detection technology that can quickly and accurately identify molecular targets within patient samples without the need for purification or extraction of target molecules from the sample. T2MR eliminates these time- and labor-intensive steps. The T2MR diagnostic signal is not compromised or disrupted by the sample background, even for highly complex sample backgrounds present in blood from patients suspected of having sepsis.
Thousandfold increase in detection sensitivity
The number of cells required for blood culture positivity is typically in the range of 10,000 to 1,000,000 CFUs/mL. This is more than a thousandfold increase in the number of cells required for T2MR detection direct from whole blood. The T2MR-powered T2Dx® Instrument can detect organisms as low as 1 CFU/mL, enabling it to be the only FDA-cleared technology that can detect low levels of pathogens in whole blood.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
New @OFIDJournal article on Sepsis and COVID-19 provides a “call to action” to change the dynamic of dealing with sepsis. Authors advocate for widespread adoption and implementation of rapid diagnostics, including culture-independent diagnostics.